Figure 2: MST analysis of glyco-modified pertuzumab binding with HER2, CD16a and FcRn.
From: Glycoengineering of pertuzumab and its impact on the pharmacokinetic/pharmacodynamic properties
Human HER2, CD16a, and FcRn were labeled by RED-NHS. Four glyco-modified pertuzumabs, pertuzumabFuc+SA+ type (black dotted line), pertuzumabFuc+SA− type (red dotted line), pertuzumabFuc−SA+ type (blue dotted line) and pertuzumabFuc−SA− type (green dotted line) were mixed with fluorophore-labeled ligands respectively. The thermophoretic mobility was measured by a MST machine. The binding data were analyzed by Prism. (A) HER2, (B) CD17a Val176, (C) CD16a Phe176 and (D) FcRn. Data are presented as mean values ± SD. Data are representative of three independent experiments with similar results (n = 3). Fuc: fucose, SA: Sialic acid.
